Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe–Based Single-Nucleotide Polymorphism Array

Journal of Molecular Diagnostics

Volumn 18, Issue 5, 2016, Pages 676-687

  Singh, Rajesh R ^a   Mehrotra, Meenakshi ^a   Chen, Hui ^a   Almohammedsalim, Alaa A ^a   Sahin, Ayesagul ^a   Bosamra, Alex ^a   Patel, Keyur P ^a   Routbort, Mark J ^a   Lu, Xinyan ^a   Ronald, Abraham ^a   Mishra, Bal Mukund ^a   Virani, Shumaila ^a   Medeiros, L Jeffrey ^a   Luthra, Rajyalakshmi ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FORMALDEHYDE; K RAS PROTEIN; MYC PROTEIN; PARAFFIN; TUMOR MARKER;

ARTICLE; CANCER CELL LINE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE COPY NUMBER ABERRATION; GENE DOSAGE; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIMIT OF DETECTION; MALE; MOLECULAR INVERSION PROBE ARRAY; MOLECULAR PROBE; NEXT GENERATION SEQUENCING; REPRODUCIBILITY; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; TUMOR GENE; CHROMOSOMAL MAPPING; COPY NUMBER VARIATION; GENETICS; GENOMICS; HETEROZYGOSITY LOSS; HIGH THROUGHPUT SEQUENCING; NEOPLASMS; PROCEDURES; PROTO ONCOGENE; SENSITIVITY AND SPECIFICITY; WORKFLOW;

BIOMARKERS, TUMOR; CHROMOSOME MAPPING; DNA COPY NUMBER VARIATIONS; FEMALE; GENE DOSAGE; GENES, ERBB-1; GENES, ERBB-2; GENETIC TESTING; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; MALE; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; WORKFLOW;

EID: 84991232765     PISSN: 15251578     EISSN: 19437811     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2016.03.008     Document Type: Article

References (36)

1. 1 Ciriello, G., Miller, M.L., Aksoy, B.A., Senbabaoglu, Y., Schultz, N., Sander, C., Emerging landscape of oncogenic signatures across human cancers. Nat Genet 45 (2013), 1127–1133.
2. 2 Endesfelder, D., Burrell, R.A., Kanu, N., McGranahan, N., Howell, M., Parker, P.J., Downward, J., Swanton, C., Kschischo, M., Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer. Cancer Res 74 (2014), 4853–4863.
3. 3 Hieronymus, H., Schultz, N., Gopalan, A., Carver, B.S., Chang, M.T., Xiao, Y., Heguy, A., Huberman, K., Bernstein, M., Assel, M., Murali, R., Vickers, A., Scardino, P.T., Sander, C., Reuter, V., Taylor, B.S., Sawyers, C.L., Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci U S A 111 (2014), 11139–11144.
4. 4 Huw, L.Y., O'Brien, C., Pandita, A., Mohan, S., Spoerke, J.M., Lu, S., Wang, Y., Hampton, G.M., Wilson, T.R., Lackner, M.R., Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer. Oncogenesis, 2, 2013, e83.
5. 5 Martin, V., Corso, S., Comoglio, P.M., Giordano, S., Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence. Mol Oncol 8 (2014), 1561–1574.
6. 6 Park, R.W., Kim, T.M., Kasif, S., Park, P.J., Identification of rare germline copy number variations over-represented in five human cancer types. Mol Cancer, 14, 2015, 25.
7. 7 Yang, W., Yao, Y.W., Zeng, J.L., Liang, W.J., Wang, L., Bai, C.Q., Liu, C.H., Song, Y., Prognostic value of FGFR1 gene copy number in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis 6 (2014), 803–809.
8. 8 Alentorn, A., Sanson, M., Mokhtari, K., Marie, Y., Hoang-Xuan, K., Delattre, J.Y., Idbaih, A., Insights revealed by high-throughput genomic arrays in nonglial primary brain tumors. Expert Rev Mol Diagn 12 (2012), 265–277.
9. 9 Kousoulidou, L., Sismani, C., Patsalis, P.C., Multiplex amplifiable probe hybridization (MAPH) methodology as an alternative to comparative genomic hybridization (CGH). Methods Mol Biol 653 (2010), 47–71.
10. 10 LaFramboise, T., Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances. Nucleic Acids Res 37 (2009), 4181–4193.
11. 11 Simons, A., Sikkema-Raddatz, B., de Leeuw, N., Konrad, N.C., Hastings, R.J., Schoumans, J., Genome-wide arrays in routine diagnostics of hematological malignancies. Hum Mutat 33 (2012), 941–948.
12. 12 Chamizo, C., Rojo, F., Madoz-Gurpide, J., Determination of true ERBB2 gene amplification in breast cancer by quantitative PCR using a reference and a novel control gene. Appl Immunohistochem Mol Morphol 24 (2016), 179–187.
13. 13 Savino, M., Parrella, P., Copetti, M., Barbano, R., Murgo, R., Fazio, V.M., Valori, V.M., Carella, M., Garrubba, M., Santini, S.A., Comparison between real-time quantitative PCR detection of HER2 mRNA copy number in peripheral blood and ELISA of serum HER2 protein for determining HER2 status in breast cancer patients. Cell Oncol 31 (2009), 203–211.
14. 14 Heinrichs, S., Li, C., Look, A.T., SNP array analysis in hematologic malignancies: avoiding false discoveries. Blood 115 (2010), 4157–4161.
15. 15 van Engen-van Grunsven, A.C., Baar, M.P., Pfundt, R., Rijntjes, J., Kusters-Vandevelde, H.V., Delbecq, A.L., Keunen, J.E., Klevering, J.B., Wesseling, P., Blokx, W.A., Groenen, P.J., Whole-genome copy-number analysis identifies new leads for chromosomal aberrations involved in the oncogenesis and metastastic behavior of uveal melanomas. Melanoma Res 25 (2015), 200–209.
16. 16 Schouten, P.C., Grigoriadis, A., Kuilman, T., Mirza, H., Watkins, J.A., Cooke, S.A., van Dyk, E., Severson, T.M., Rueda, O.M., Hoogstraat, M., Verhagen, C., Natrajan, R., Chin, S.F., Lips, E.H., Kruizinga, J., Velds, A., Nieuwland, M., Kerkhoven, R.M., Krijgsman, O., Vens, C., Peeper, D., Nederlof, P.M., Caldas, C., Tutt, A.N., Wessels, L.F., Linn, S.C., Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms. Mol Oncol 9 (2015), 1274–1286.
17. 17 Alexiev, B.A., Zou, Y.S., Clear cell papillary renal cell carcinoma: a chromosomal microarray analysis of two cases using a novel Molecular Inversion Probe (MIP) technology. Pathol Res Pract 210 (2014), 1049–1053.
18. 18 Kusters-Vandevelde, H.V., van Engen-van Grunsven, I.A., Coupland, S.E., Lake, S.L., Rijntjes, J., Pfundt, R., Kusters, B., Wesseling, P., Blokx, W.A., Groenen, P.J., Mutations in G protein encoding genes and chromosomal alterations in primary leptomeningeal melanocytic neoplasms. Pathol Oncol Res 21 (2015), 439–447.
19. 19 Hasselblatt, M., Isken, S., Linge, A., Eikmeier, K., Jeibmann, A., Oyen, F., Nagel, I., Richter, J., Bartelheim, K., Kordes, U., Schneppenheim, R., Fruhwald, M., Siebert, R., Paulus, W., High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. Genes Chromosomes Cancer 52 (2013), 185–190.
20. 20 Thompson, P.A., Ljuslinder, I., Tsavachidis, S., Brewster, A., Sahin, A., Hedman, H., Henriksson, R., Bondy, M.L., Melin, B.S., Loss of LRIG1 locus increases risk of early and late relapse of stage I/II breast cancer. Cancer Res 74 (2014), 2928–2935.
21. 21 Foster, J.M., Oumie, A., Togneri, F.S., Vasques, F.R., Hau, D., Taylor, M., Tinkler-Hundal, E., Southward, K., Medlow, P., McGreeghan-Crosby, K., Halfpenny, I., McMullan, D.J., Quirke, P., Keating, K.E., Griffiths, M., Spink, K.G., Brew, F., Cross-laboratory validation of the OncoScan(R) FFPE Assay, a multiplex tool for whole genome tumour profiling. BMC Med Genomics, 8, 2015, 5.
22. 22 Millson, A., Lagrave, D., Willis, M.J., Rowe, L.R., Lyon, E., South, S.T., Chromosomal loss of 3q26.3-3q26.32, involving a partial neuroligin 1 deletion, identified by genomic microarray in a child with microcephaly, seizure disorder, and severe intellectual disability. Am J Med Genet A 158A (2012), 159–165.
23. 23 Baughn, L.B., Biegel, J.A., South, S.T., Smolarek, T.A., Volkert, S., Carroll, A.J., Heerema, N.A., Rabin, K.R., Zweidler-McKay, P.A., Loh, M., Hirsch, B., Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study. Cancer Genet 208 (2015), 1–18.
24. 24 Lloyd, I.E., Rowe, L.R., Erickson, L.K., Paxton, C.N., South, S.T., Alashari, M., Two cases of Scimitar syndrome associated with multiple congenital skeletal anomalies and lacking abnormalities by genomic microarray analysis. Pediatr Dev Pathol 17 (2014), 360–365.
25. 25 Singh, R.R., Patel, K.P., Routbort, M.J., Reddy, N.G., Barkoh, B.A., Handal, B., Kanagal-Shamanna, R., Greaves, W.O., Medeiros, L.J., Aldape, K.D., Luthra, R., Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn 15 (2013), 607–622.
26. 26 Singh, R.R., Patel, K.P., Routbort, M.J., Aldape, K., Lu, X., Manekia, J., Abraham, R., Reddy, N.G., Barkoh, B.A., Veliyathu, J., Medeiros, L.J., Luthra, R., Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. Br J Cancer 111 (2014), 2014–2023.
27. 27 Yan, M., Parker, B.A., Schwab, R., Kurzrock, R., HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev 40 (2014), 770–780.
28. 28 Liu, L., Backlund, L.M., Nilsson, B.R., Grander, D., Ichimura, K., Goike, H.M., Collins, V.P., Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med (Berl) 83 (2005), 917–926.
29. 29 Dacic, S., Flanagan, M., Cieply, K., Ramalingam, S., Luketich, J., Belani, C., Yousem, S.A., Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol 125 (2006), 860–865.
30. 30 Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M.A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., Gillett, C., Grigoriadis, A., Tutt, A., Reis-Filho, J.S., Ashworth, A., FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70 (2010), 2085–2094.
31. 31 Dutt, A., Ramos, A.H., Hammerman, P.S., Mermel, C., Cho, J., Sharifnia, T., Chande, A., Tanaka, K.E., Stransky, N., Greulich, H., Gray, N.S., Meyerson, M., Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One, 6, 2011, e20351.
32. 32 Sargent, R., Jones, D., Abruzzo, L.V., Yao, H., Bonderover, J., Cisneros, M., Wierda, W.G., Keating, M.J., Luthra, R., Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia. J Mol Diagn 11 (2009), 25–34.
33. 33 Ramkissoon, S.H., Bi, W.L., Schumacher, S.E., Ramkissoon, L.A., Haidar, S., Knoff, D., et al. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol 17 (2015), 1344–1355.
34. 34 Wang, L., Rao, M., Fang, Y., Hameed, M., Viale, A., Busam, K., Jhanwar, S.C., A genome-wide high-resolution array-CGH analysis of cutaneous melanoma and comparison of array-CGH to FISH in diagnostic evaluation. J Mol Diagn 15 (2013), 581–591.
35. 35 Bousamra, A.C.H., Luthra, R., Lu, X., Aldape, K.D., Singh, R.R., Lu, G., Abraham, R., Virani, S., Robinson, M., Mishra, B.M., Sahin, A.A., Molecular inversion probe technology generates high-quality HER2 copy number data in formalin-fixed paraffin embedded breast cancer tissue. J Cancer Clin Oncol, 1, 2015, 100102.
36. 36 Wolff, A.C., Hammond, M.E., Hicks, D.G., Dowsett, M., McShane, L.M., Allison, K.H., Allred, D.C., Bartlett, J.M., Bilous, M., Fitzgibbons, P., Hanna, W., Jenkins, R.B., Mangu, P.B., Paik, S., Perez, E.A., Press, M.F., Spears, P.A., Vance, G.H., Viale, G., Hayes, D.F., Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31 (2013), 3997–4013.